- Home
- CTSO vs CLSD Comparison
CTSO vs CLSD Comparison
Compare CTSO & CLSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTSO
- CLSD
- Stock Information
- Founded
- CTSO 1997
- CLSD 2011
- Country
- CTSO United States
- CLSD United States
- Employees
- CTSO N/A
- CLSD N/A
- Industry
- CTSO Medical/Dental Instruments
- CLSD Biotechnology: Pharmaceutical Preparations
- Sector
- CTSO Health Care
- CLSD Health Care
- Exchange
- CTSO Nasdaq
- CLSD Nasdaq
- Market Cap
- CTSO 52.6M
- CLSD 59.1M
- IPO Year
- CTSO N/A
- CLSD 2016
- Fundamental
- Price
- CTSO $1.03
- CLSD $0.80
- Analyst Decision
- CTSO Buy
- CLSD Strong Buy
- Analyst Count
- CTSO 2
- CLSD 4
- Target Price
- CTSO $5.50
- CLSD $4.75
- AVG Volume (30 Days)
- CTSO 134.9K
- CLSD 402.9K
- Earning Date
- CTSO 08-12-2025
- CLSD 08-11-2025
- Dividend Yield
- CTSO N/A
- CLSD N/A
- EPS Growth
- CTSO N/A
- CLSD N/A
- EPS
- CTSO N/A
- CLSD N/A
- Revenue
- CTSO $35,332,238.00
- CLSD $3,764,000.00
- Revenue This Year
- CTSO $18.34
- CLSD $60.52
- Revenue Next Year
- CTSO $19.82
- CLSD $88.28
- P/E Ratio
- CTSO N/A
- CLSD N/A
- Revenue Growth
- CTSO 15.37
- CLSD N/A
- 52 Week Low
- CTSO $0.71
- CLSD $0.70
- 52 Week High
- CTSO $1.61
- CLSD $1.65
- Technical
- Relative Strength Index (RSI)
- CTSO 49.00
- CLSD 50.60
- Support Level
- CTSO $0.93
- CLSD $0.79
- Resistance Level
- CTSO $1.39
- CLSD $0.82
- Average True Range (ATR)
- CTSO 0.13
- CLSD 0.04
- MACD
- CTSO -0.02
- CLSD 0.00
- Stochastic Oscillator
- CTSO 34.92
- CLSD 52.50
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.